Noopept
GVS-111 / N-Phenylacetyl-L-prolylglycine ethyl ester / Omberacetam
A dipeptide-derived nootropic (a Pro-Gly derivative) developed in Russia. Though structurally related to piracetam, it is taken at much lower doses; rat studies show increased NGF and BDNF and effects on AMPA and NMDA receptors. It is registered in Russia as an over-the-counter medicine and is rapidly converted to the active metabolite cyclo-prolylglycine.
Half-life
~5–10 minutes (parent compound; active metabolite cyclo-prolylglycine persists hours)
Typical Dose
10–30 mg/day oral; 10 mg sublingual
18/30Route
oral
Category
neuroprotective
Evidence Overview
Strength of evidence across clinical, expert, and experimental lanes.
How Noopept is dosed in practice
Usually taken by mouth. Typical range: 10–30 mg/day oral; 10 mg sublingual. Half-life: ~5–10 minutes (parent compound; active metabolite cyclo-prolylglycine persists hours). Each card gives the dose, frequency and duration from one evidence lane: Clinical (human trials), Expert (practitioner protocols) or Experimental (early or animal data). These ranges describe what has been studied or used; they are not a prescription.
Work out the units to draw with the reconstitution calculator, how long a vial lasts with the vial duration calculator, and how levels fall between doses with the half-life calculator.
Registered in Russia as an over-the-counter 10 mg tablet for memory and attention problems after brain injury, post-concussion syndrome, cerebrovascular insufficiency and fatigue states. Small Russian open studies at 20 mg/day reported cognitive improvement; the NGF and BDNF increases come from rat studies.
- Russian product label
- Open study after stroke (2011)
- Russian clinical studies (2008, 2009)
One of the most popular nootropic compounds globally. Practitioners recommend starting at 10 mg oral or sublingual and titrating. Sublingual route provides faster onset. Must cycle to prevent tolerance. Co-supplement with choline source (alpha-GPC or CDP-choline).
- Nootropic practitioner protocols
- Cognitive enhancement specialist recommendations
- International nootropic community consensus
Extremely popular in the nootropic community with thousands of user reports. Consistent reports of improved verbal fluency, memory recall, and dream vividness. Sublingual onset in 15–20 minutes. Some users report emotional blunting at higher doses (>30 mg/day). Generally well-tolerated.
- Reddit r/Nootropics — Noopept megathread (thousands of reports)
- Longecity forum — extensive user experience database
- Examine.com — Noopept research summary
Unlock Full Evidence Sources
Get complete clinical data, expert protocols, and experimental research for Noopept and 90+ other compounds with Pro.
Upgrade to ProSafety & Contraindications
- Pregnancy or breastfeeding
- Severe hepatic impairment (hepatic metabolism required)
- Lactose intolerance (tablet formulations may contain lactose)
Noopept: common questions
What is Noopept?
A dipeptide-derived nootropic (a Pro-Gly derivative) developed in Russia. Though structurally related to piracetam, it is taken at much lower doses; rat studies show increased NGF and BDNF and effects on AMPA and NMDA receptors. It is registered in Russia as an over-the-counter medicine and is rapidly converted to the active metabolite cyclo-prolylglycine.
How is Noopept dosed?
Noopept is usually taken by mouth. Typical range in DoseCraft's library: 10–30 mg/day oral; 10 mg sublingual. Clinical (human trials): 20–30 mg/day oral (10 mg two to three times daily), per the Russian label; 10 mg twice daily, up to three times daily, after meals and not in the evening; 1.5–3 month course; 2 months in a stroke study (2011). Expert (practitioner protocols): 10–30 mg/day oral or sublingual; 2–3 times daily, 10 mg per dose; 6–8 week cycles with 2–4 week breaks. Experimental (early or animal data): 10–30 mg/day; 2–3 times daily; Cycled 6–8 weeks on, 2–4 weeks off. These ranges describe what has been studied or used; they are not a prescription.
Is Noopept FDA-approved?
No. Noopept is not FDA-approved. It is an approved medicine in Russia; that approval applies there only, not in the US.
What is the half-life of Noopept?
DoseCraft's library lists a half-life of ~5–10 minutes (parent compound; active metabolite cyclo-prolylglycine persists hours). Half-life sets how often a compound is dosed and how long it takes to clear: about five half-lives.
Who should not use Noopept?
Listed contraindications: Pregnancy or breastfeeding; Severe hepatic impairment (hepatic metabolism required); Lactose intolerance (tablet formulations may contain lactose).
Information is for educational purposes only. Always consult a licensed healthcare provider before starting any peptide regimen.
Page updated . How we grade evidence: methodology.